NCT02489461 - Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 5, 2014

Primary Completion Date

April 5, 2016

Study Completion Date

September 18, 2017

Conditions

HIV-1-infection

Interventions

DRUG

VM-1500

VM-1500 up to 96 weeks

DRUG

Efavirenz

Efavirenz up to 48 weeks

DRUG

Antiretroviral therapy (ART)

Antiretroviral therapy up to 96 weeks

Trial Locations (13)

Central Scientific Research Institute of Epidemiology, Moscow

Moscow Infectional Clinical Hospital #2, Moscow

Moscow Prevention AIDS Center, Moscow

St.Petersburg city center for AIDS prevention, Saint Petersburg

"Clinical infectious diseases hospital n.a. S.P. Botkin", Saint Petersburg

Ryazan Regional Clinical Dermatovenerologic Dispensary, Ryazan

Lipetsk regional center for AIDS prevention, Lipetsk

Volgograd regional center for AIDS prevention, Volgograd

Republican hospital for AIDS prevention, Kazan'

Udmurtia Republican hospital for AIDS prevention, Izhevsk

City center for AIDS prevention, Tolyatti

Perm Regional center for AIDS prevention, Perm

Kaluga regional center for AIDS prevention, Kaluga